

Article

Protection-Free Strategy for the Synthesis of Boro-Depsipeptides in Aqueous Media under Microwave-Assisted Conditions

Shuo-Bei Qiu ¹, Pei-Yao Liu ², Bo-Cheng Wang ³, Pin-Rui Chen ³, Jing-Han Xiao ³, Ting-Yu Hsu ³, Kuan-Lin Pan ³, Zhi-Yin Lai ³, Yi-Wei Chen ⁴, Ying-Chuan Chen ^{2,*}, Jen-Kun Chen ^{1,5,*} and Po-Shen Pan ^{3,*}

- ¹ Graduate Institute of Life Science, National Defense Medical Center, No. 161, Sec. 6, Minquan E. Rd., Neihu Dist., Taipei City 11490, Taiwan, Republic of China; gloria919147@gmail.com
- ² Department of Physiology & Biophysics, National Defense Medical Center, No. 161, Sec. 6, Minquan E. Rd., Neihu Dist., Taipei City 11490, Taiwan, Republic of China; peiyao101@gmail.com
- ³ Department of Chemistry, College of Sciences, Tamkang University, No. 151, Yingzhuan Rd., Danshui Dist., New Taipei City 25137, Taiwan, Republic of China; bcw@mail.tku.edu.tw (B.-C.W.); shawn19991002@gmail.com (P.-R.C.); a0952389829@gmail.com (J.-H.X.); lydia1020552@gmail.com (T.-Y.H.); ss870119@gmail.com (K.-L.P.); aa0935900324@gmail.com (Z.-Y.L.)
- ⁴ Department of Oncology, Taipei Veterans General Hospital, No. 201, Sec. 2, Shipai Rd., Beitou District, Taipei City 11217, Taiwan, Republic of China; chenyw@vghtpe.gov.tw
- ⁵ Center for Nanomedicine Research, National Health Research Institutes, Zhunan, Miaoli County 35053, Taiwan, Republic of China
- * Correspondence: addy0918@gmail.com (Y.-C.C.); jkchen@nhri.edu.tw (J.-K.C.); 138020@gms.tku.edu.tw (P.-S.P.)



Citation: Qiu, S.-B.; Liu, P.-Y.; Wang, B.-C.; Chen, P.-R.; Xiao, J.-H.; Hsu, T.-Y.; Pan, K.-L.; Lai, Z.-Y.; Chen, Y.-W.; Chen, Y.-C.; et al. Protection-Free Strategy for the Synthesis of Boro-Depsipeptides in Aqueous Media under Microwave-Assisted Conditions. *Molecules* **2022**, *27*, 2325. <https://doi.org/10.3390/molecules27072325>

Academic Editors: Luca D. D'Andrea and György Keglevich

Received: 28 January 2022

Accepted: 30 March 2022

Published: 4 April 2022

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

Abstract: In this report, 19 boron-containing depsipeptides were synthesized via microwave-assisted Passerini three-component reaction (P-3CR) in an aqueous environment. The linker-free DAHMI fluorescent tagging approach was used on selected boron-containing compounds to study the relationship between their structures and their level of cellular uptake of HEK293 cells. The biological data retrieved from the DAHMI experiments indicated that while the structures of tested compounds may be highly similar, their bio-distribution profile could be vastly distinctive. The reported optimized one-pot synthetic strategy along the linker-free in vitro testing protocol could provide an efficient platform to accelerate the development of boron-containing drugs.

Keywords: depsipeptide(s); α -acyloxyamide; passerini; multicomponent; microwave-assisted; DAHMI; boronic acid

1. Introduction

Boronic acids are important entities for a broad spectrum of applications [1]. Although they were widely recognized as the vital building blocks in varieties of synthetic reactions [2], boron-containing entities were also exploited as the flame retardant materials [3], semi-conducting materials [4], boron carrier agents for the boron neutron capture therapy [5], enzyme inhibitors [6], and also as the insecticide [7]. In particular, boron-based pharmaceuticals have gained much attention and success for the past decades. Unlike most pharmaceuticals that rely on non-covalent interactions with their biological targets, boron-containing compounds form a reversible covalent bond between their targets. This unique advantage makes such compounds have a high affinity toward their targets with relatively low molecular weight [6]. In 2003, the first boronic acid, Bortezomib (Velcade[®]), was approved by the U.S. FDA to treat multiple myeloma. Since then, a series of boron-containing molecules are either in different stages of clinical trials or have been approved by the U.S. FDA (Figure 1).




Figure 1. Boron-containing pharmaceuticals.

Due to the presence of an empty *p*-orbital, boronic acids are exceptional candidates for inhibiting hydrolytic enzymes, which are often overexpressed in ranges of diseases [8]. The strategies involved in the making of boronic acid analogues often demand the protection of the boronic acid group prior to any synthetic operations. However, removing the protecting group often requires a harsh condition or extended reaction period, making this process remarkably unfavorable. In addition, the purification of boron-containing substrates after each synthetic step has proven challenging and is considered an intense labor operation [9]. In this regard, the direct synthesis of boronic acids using unprotected boron building blocks via a one-pot multicomponent reaction is highly desirable [10].

One of the most realized multicomponent reactions, Passerini three-component reaction (P-3CR) has been extensively used in medicinal programs to generate depsipeptide analogues. It has successfully led to the discovery of numerous U.S. FDA approval drugs such as Diltiazem (Cardizem™), Trimethadione (Tridione™), Paramethadione (Paradione™), Camazepam (Albego™), Roxatidine (Roxit™) and Fusafungine (Locabital™). In 2018, Eduardo Peña-Cabrera and co-workers published their work on using formyl aryl boronic acids as one of the building blocks to construct a series of Passerini analogues [11]. In the following year, Alexander Dömling and co-workers reported that a series of free phenylboronic acids were utilized as building blocks in numerous IMCR platforms, including P-3CR [12]. Both reports have demonstrated that free boronic acids could be utilized directly in IMCRs. Inspired by their work, we developed microwave-assisted conditions that allow the rapid assembly of a series of P-3CR analogues by unprotected phenylformyl/phenylcarboxyl boronic acids. The reactions are environmentally benign as they proceed in H₂O, and the crudes could be simply purified by acid/base extractions and re-crystallization.


2. Results and Discussion

2.1. Chemistry

In this report, two series of boron-containing P-3CR analogues were synthesized. Synthetic conditions for each series were optimized correspondingly and are summarized in Tables 1 and 2. The first series of compounds were synthesized using boron-containing aldehyde as one of the building blocks, and the optimization processes are summarized in Table 1. Four commonly used polar solvents were utilized for the direct synthesis of depsipeptide boronic acid **4a** (Table 1, entry 1–4). It was found that under room temperature, only H₂O gave the desired product in 2.5 h (Table 1, entry 4). Increasing the reaction temperature from room temperature to 45 °C with H₂O significantly improved the yield from 5% to 56% (Table 1, entry 6). It is important to note that, at 45 °C, the one with

microwave irradiation (Table 1, entry 8, 68%) gave a higher yield than the one with the oil bath (Table 1, entry 6, 56%). This could be the consequence of the more efficient energy input by the microwave heating condition. Higher temperatures were also tested (Table 1, entry 10–11); however, the yields were either similar (65 °C) or decreased (85 °C). Reducing the reaction time from 2.5 h to 1 h gave a lower yield (Table 1, entry 7, 55%), indicating the reaction has yet to be completed. However, increasing the reaction time to 4 h (Table 1, entry 9, 33%) does not benefit the yield. Presumably, the side reactions were taking place where we observed the increased number of unidentified signals from the crude ^1H NMR spectrum. Hence the optimal condition was to react in H_2O under microwave-assisted heating at 45 °C for 2.5 h (Table 1, entry 8).

Table 1. Optimization of P-3CR using formylphenyl boronic acids **2**^{a,b,c}.




| Entry | Solvent | <i>t</i> (°C) | Time (h) | Yield (%) |
|-------|----------------------|---------------|----------|-----------|
| 1 | Ether | 25 | 2.5 | ND |
| 2 | DCM | 25 | 2.5 | ND |
| 3 | MeOH | 25 | 2.5 | ND |
| 4 | H_2O | 25 | 2.5 | 5 |
| 5 | H_2O | 25 | 24 | 57 |
| 6 | H_2O | 45 | 2.5 | 56 |
| 7 | H_2O | MW, 45 | 1.0 | 55 |
| 8 | H_2O | MW, 45 | 2.5 | 68 |
| 9 | H_2O | MW, 45 | 4.0 | 33 |
| 10 | H_2O | MW, 65 | 2.5 | 63 |
| 11 | H_2O | MW, 85 | 2.5 | 53 |

^a Reaction conditions: **1a** (1.2 equiv), **2a** (1.0 equiv) and **3a** (1.2 equiv) were stirred at corresponding temperature.

^b ND = not detected. ^c Isolated yield.

With the optimized condition in hand, seven of the additional compounds were synthesized (**4a–g**), and the results were summarized in Scheme 1.

Initially, the optimal condition retrieved from Table 1 was applied to construct second series of analogues, in which the boron-containing benzoic acids were used as one of the building blocks (Table 2, entry 4). It was found that the yield would be significantly improved if the reaction temperature was raised from ambient temperature to 85 °C under microwave-irradiation condition (Table 2, entry 1, 4–6). However, a significant decline in yield was observed when the temperature reached 95 °C. Presumably, because the boiling point of the *t*-butyl isocyanide is 91 °C, rendering the reaction proceeded without the presence of the sufficient *t*-butyl isocyanide (Table 2, entry 7). It is noteworthy that at 85 °C, the one with microwave irradiation (Table 2, entry 6, 89%) gave a higher yield than the one with the oil bath (Table 2, entry 3, 53%). This should also contribute to the more efficient energy input by the microwave heating condition.




^aReaction conditions: **1** (1.2 equiv), **2** (1.0 equiv) and **3** (1.2 equiv) were added to solvent (H₂O) and stirred at MW, 45 °C for 2.5 h.

^bIsolated yield.

^cReaction conditions: **1** (1.2 equiv), **2** (1.0 equiv) and **3** (1.2 equiv) were added to solvent (H₂O) and stirred at 25 °C for 2.5 h.

Scheme 1. Synthesis of P-3CR boronic acids **4** using formylphenyl boronic acids **2** ^{a,b}.

Table 2. Optimization of P-3CR using boronobenzoic acids **1** ^{a,b}.




| Entry | Solvent | <i>t</i> (°C) | Time (h) | Yield (%) |
|-------|------------------|---------------|----------|-----------|
| 1 | H ₂ O | 25 | 2.5 | 63 |
| 2 | H ₂ O | 25 | 24 | 62 |
| 3 | H ₂ O | 85 | 2.5 | 53 |
| 4 | H ₂ O | MW, 45 | 2.5 | 55 |
| 5 | H ₂ O | MW, 65 | 2.5 | 74 |
| 6 | H ₂ O | MW, 85 | 2.5 | 89 |
| 7 | H ₂ O | MW, 95 | 2.5 | 53 |

^a Reaction conditions: **1b** (1.2 equiv), **2b** (1.0 equiv) and **3a** (1.2 equiv) were stirred at corresponding temperature.

^b Isolated yield.

With the optimized condition in hand, the second series of P-3CR analogues (**5a–l**) were prepared (Scheme 2).



^aReaction conditions: **1** (1.2 equiv), **2** (1.0 equiv) and **3** (1.2 equiv) were added to solvent (H₂O) and stirred at MW, 85 °C for 2.5 h.

^bIsolated yield.

^cReaction conditions: **1** (1.2 equiv), **2** (1.0 equiv) and **3** (1.2 equiv) were added to solvent (H₂O) and stirred at 25 °C for 2.5 h.

Scheme 2. Synthesis of P-3CR boronic acids **5** using boronobenzoic acids **1** ^{a, b}.

2.2. Theoretical Calculations

Although the desired compounds were constructed via the Passerini reaction, we noticed that simply replacing a boron-containing aldehyde with its carboxylic acid counterpart would considerably improve the yield from 8% (Scheme 1, **4f**) to 21% (Scheme 2, **5d**) under the same synthetic condition. This result indicated that the location of the boronic acid group might play a critical role in determining the outcome of the P-3CR. A series of theoretical calculations and spectroscopic studies were executed to further investigate how the boron group engages the reaction mechanism.

Due to an empty *p*-orbital, boron is prone to nucleophilic attack [13]. Therefore, we hypothesized that adding the building block with the boronic acid group in P-3CR could alter the overall reaction mechanism. For instance, when an isocyanide approaches the boron-containing protonated aldehyde substrate (PAS), it could either attack the boronic acid group (Figure 2a, pathway A) or the protonated aldehyde group (Figure 2a, pathway B). Likewise, when the boron-containing carboxylate substrate (CS) was used, the isocyanide could attack not only the nitrilium intermediate but also the boronic acid group (Figure 2b, pathway C) or the carboxylate group (Figure 2b, pathway D).




Figure 2. Postulate mechanistic model of P-3CR that involves (a) formylphenyl Boronic Acid (PAS); (b) Boronobenzoic Acid (CS).

To corroborate how isocyanide engaged between the protonated aldehyde group or the carboxylate group, a series of theoretical calculations were executed using a DFT/B3LYP/6-31G(d,p) method. It was found that when the protonated aldehyde substrate (PAS) was presented in the phenylboronic acid system (Table 3, entry 1, LUMO-side/top), the electron density of the phenyl group did not delocalize to the boron's empty *p*-orbital. In other words, it increases the possibility of isocyanide attacking the boronic acid group. On the other hand, when the phenylboronic acid was attached to the carboxylate substrate (CS), the electron density of the phenyl group delocalized to the boron's empty *p*-orbital, which protected it from being attacked by the isocyanide (Table 3, entry 2, LUMO-side/top).

Table 3. Electron density diagram of HOMO/LUMO states in PAS and CS.

| Entry | Dihedral Angle | HOMO-Side | LUMO-Side | HOMO-Top | LUMO-Top |
|-------|----------------|-----------|-----------|----------|----------|
| 1 | 0.00069° | | | | |
| 2 | −0.01869° | | | | |

Projected density of state (pDOS) analysis of the HOMO and LUMO states of boron-containing PAS and CS systems was also obtained using the DFT/B3LYP/6-31G(d,p) method, and the results are summarized in Table 4. It was found that when the protonated formyl group is presented, the relative charge density of boron was 0.73 in the LUMO state (Table 4, entry 1); however, when the carboxylate group is presented, it increased drastically to 19.85 (Table 4, entry 2). These results implied that when the electron-withdrawing protonated aldehyde group is presented, it is prone to nucleophilic attack from the isocyanide. On the other hand, when an electron-donating carboxylate is presented, the delocalization of the electrons from the phenyl group protects the boronic acid from such an attack.

Table 4. Calculated projected density of state values (pDOS, %) for the HOMO/LUMO orbital of PAS and CS.

| Entry | Dihedral Angle | HOMO | | | | LUMO | | | |
|-------|----------------|------|------|-------|-------|-------|-------|-------|-------|
| | | OO | B | Ph | COHH | OO | B | Ph | COHH |
| 1 | PAS 0.00069° | 1.14 | 0.00 | 98.69 | 0.17 | 2.16 | 0.73 | 39.08 | 58.03 |
| 2 | CS −0.01869° | 0.02 | 0.00 | 14.18 | 85.80 | 11.42 | 19.85 | 64.04 | 4.70 |

Two model reactions were carried out in the NMR tubes to validate the abovementioned theoretical calculations, and their corresponding ^{11}B NMR spectrums are shown below (Figure 3).




Figure 3. Two model reactions for ^{11}B NMR Study (a) Model A: Passerini-3CR with formylphenyl boronic acid; (b) Model B: Passerini-3CR with boronobenzoic acid.

The in-situ ^{11}B NMR studies of P-3CR have shown that when a boron-containing aldehyde is used (Figure 3a, Model A), a signal representing the formation of tetra-coordinate boron at 18.66 ppm emerged right next to a tri-coordinate boronic acid signal (27.18 ppm). On the other hand, when a boron-containing carboxylic acid was used (Figure 3b, Model B), the tetra-coordinate boron signal was almost unnoticeable. The results were in line with the theoretical calculations and explained how a boron-containing building block impacted the overall results of the multicomponent reaction. To the best of our knowledge, this is the first report discussing the involvement of boronic acid in the isocyanide-based multicomponent reaction.

2.3. In Vitro Studies

One of the critical aspects of developing a pharmaceutical agent is to elucidate its bio-distribution profile fully. The study often involves placing the fluorescent tag onto the analogs via a suitable linker. The whole process involves labor-intensive efforts and is often considered as the bottleneck of the drug discovery program.

Boron Neutron Capture Therapy (BNCT) is a binary biochemically targeted radiotherapy where the boron carrier agent and thermal neutron are both required to execute the treatment procedure. Compared to conventional radiation therapy and chemotherapy, BNCT can destroy the tumor cells while leaving normal tissues unharmed. One of the gold standards required for the ideal boron delivery agent is low toxicity and high tumor uptake [14,15].





















In 2018, Eduardo Peña-Cabrera and co-workers reported a labeling strategy where a novel fluorescent tag was attached to the boronic acids via Liebeskind-Srogl cross-coupling prior to the biological evaluations. Their approach provides an outstanding alternative for cell imaging [11].

In this study, a linker-free tagging strategy specifically for the boronic acid analogs was applied. Developed by Kirihata and co-workers [16], this strategy utilizes 5-(diethylamino)-2-((methylimino)methyl)phenol (DAHMI) that can complex with the boronic acid group to show fluorescent activity in cells. Compared to the conventional boron detection approaches such as α -autoradiography [17] and immune-staining [18], this strategy offers a

much more appealing option as it requires no pre-installation of the linker and could be reliably deployed under aqueous conditions.

All compounds except **4e**, **5a**, **5h**, **5i**, **5l** (for their poor solubility issues) were subjected to the cytotoxicity experiments using the HEK293 cell line. The compounds tested are all possessed of IC_{50} values above 50 μ M (Figures S76 and S77), which is promising for use in BNCT as the boron carrier agent. Compounds **4a**, **5b**, **5f**, **5g**, and **5k** were selected for the DAHMI experiments to illustrate the importance of estimating the biodistribution profiles by the similarity of the structures between compounds, and the results were summarized in Table 5. Although it was expected to see compounds with distinctive structures such as **4a** and **5b** to have utterly different uptake patterns, we were surprised to find that even structurally similar compounds such as **5f** and **5g** also exhibited noticeable differences. Furthermore, such findings could also be found between **5g** and **5k**, in which two comparable analogs showed a completely different level of cellular uptake. Thus, contradicting the conventional aspects, the results indicated that similar analogues do not necessarily share comparable cellular bio-distribution profiles.

Table 5. Cellular bio-distribution of compound **4a**, **5b**, **5f**, **5g** and **5k**^a.

| Compound | Bright Field | DAHMI Stain ^b | Merged Image |
|---|---|---|---|
|  4a (1.0 mM) |  |  |  |
|  5b (2.0 mM) |  |  |  |
|  5f (1.0 mM) |  |  |  |
|  5g (2.0 mM) |  |  |  |
|  5g (2.0 mM) |  |  |  |

^a All compounds synthesized by Passerini-3CR in this report were racemic mixtures. ^b Cells were stained with DAHMI (2.0 mM) for 20 min at 37 °C (ex:358 nm).

3. Materials and Methods

3.1. Chemistry

3.1.1. General Information

All starting materials were obtained from commercial suppliers and used without further purification unless otherwise noted. Reactions were performed in a CEM Discover Benchmate™ microwave reactor with sealed vessels.

3.1.2. Spectroscopic Measurements

Unless otherwise specified ^1H , ^{13}C NMR and ^{11}B NMR spectra were recorded on a Bruker Avance 600 FT-NMR spectrometer at 192.5 MHz. Data are represented as follows: chemical shifts (ppm), multiplicity (s: singlet, d: doublet, t: triplet, m: multiplet, br: broad), coupling constant J (Hz). High-resolution ESI mass spectra were performed on Waters LCT Premier XE (Waters Corp., Manchester, UK).

3.1.3. General Procedure for Compound 4a–g

Carboxylic acid (1.2 equiv.), aldehyde (1.0 equiv.) and deionised H_2O (1.0 M) were treated for 6 min under microwave irradiation (45 °C, 150 W). Isocyanide (1.2 equiv.) was then added to the reaction mixture. Additional microwave irradiation was applied for 2.5 h (45 °C, 150 W) under medium speed magnetic stirring. After the reaction was completed, the crude material was concentrated and re-dissolved in dichloromethane. The resulting organic solution was then washed with 1 M HCl (aq). This was followed by adding a saturated aqueous solution of NaHCO_3 (aq) combined with brine. The resulting organic layer was collected, dried by MgSO_4 , and filtered. The filtrate was then concentrated in vacuo and the crude was precipitated by dichloromethane/ H_2O or dichloromethane/hexane sonication, and the resulting solid was collected by filtration to give the desired product 4a–g.

3.1.4. Synthesis and Characterization of Compound 4a–g

(4-(2-(tert-Butylamino)-1-(Isobutyryloxy)-2-Oxoethyl)phenyl)boronic Acid (4a)

Following general procedures, the desired compound was synthesized utilizing isobutyric acid (0.15 mL, 1.60 mmol), 4-formylphenylboronic acid (200 mg, 1.30 mmol), and tert-butyl isocyanide (0.18 mL, 1.60 mmol), giving compound 4a as a yellow oil (yield 283.9 mg, 68%). ^1H NMR (600 MHz, CD_3OD) δ 7.77 (br, 2H), 7.47 (d, $J = 7.8$ Hz, 2H), 5.86 (s, 1H), 2.71–2.67 (m, 1H), 1.29 (s, 9H), 1.20 (d, $J = 7.2$ Hz, 3H), 1.16 (d, $J = 7.2$ Hz, 3H). ^{13}C NMR (151 MHz, CD_3OD) δ 177.6, 170.2, 138.9, 135.1, 127.5, 76.8, 52.4, 35.0, 28.9, 19.4, 19.3. ^{11}B NMR (192.5 MHz, CD_3OD) δ 28.5. HRMS (ESI⁺): m/z : Calcd. for $\text{C}_{16}\text{H}_{25}\text{BNO}_5$ [$\text{M} + \text{H}$]⁺: 322.1820; Found: 322.1808.

(3-(2-(Tert-Butylamino)-1-(Isobutyryloxy)-2-Oxoethyl)phenyl)boronic Acid (4b)

Following the general procedures, the desired compound was synthesized utilizing isobutyric acid (0.07 mL, 0.80 mmol), 3-formylphenylboronic acid (100 mg, 0.66 mmol), and tert-butyl isocyanide (0.09 mL, 0.80 mmol), giving compound 4b as a yellow oil (yield 31.8 mg, 15%). ^1H NMR (600 MHz, CD_3OD) δ 7.88 (br, 1H), 7.75 (br, 1H), 7.52 (d, $J = 7.8$ Hz, 1H), 7.34 (t, $J = 7.2$ Hz, 1H), 5.86 (s, 1H), 2.72–2.67 (m, 1H), 1.30 (s, 9H), 1.21 (d, $J = 7.2$ Hz, 3H), 1.17 (d, $J = 7.2$ Hz, 3H). ^{13}C NMR (151 MHz, CD_3OD) δ 177.7, 170.5, 136.3, 135.2, 134.1, 130.2, 128.8, 77.0, 52.3, 34.9, 28.8, 19.3, 19.2. ^{11}B NMR (192.5 MHz, CD_3OD) δ 28.1. HRMS (ESI⁺): m/z : Calcd. for $\text{C}_{16}\text{H}_{25}\text{BNO}_5$ [$\text{M} + \text{H}$]⁺: 322.1820; Found: 322.1811.

(4-(2-(Tert-Butylamino)-1-(Isobutyryloxy)-2-Oxoethyl)-2-Fluorophenyl)boronic Acid (4c)

Following general procedures, the desired compound was synthesized utilizing isobutyric acid (0.06 mL, 0.71 mmol), 2-fluoro-4-phenylboronic acid (100 mg, 0.60 mmol), and tert-butyl isocyanide (0.08 mL, 0.71 mmol), giving compound 4c as a yellow oil (yield 91.6 mg, 45%). ^1H NMR (600 MHz, CD_3OD) δ 7.73 (s, 1H), 7.29 (d, $J = 7.8$ Hz, 1H), 7.19 (d, $J = 10.2$ Hz, 1H), 5.84 (s, 1H), 2.73–2.68 (m, 1H), 1.29 (s, 9H), 1.21 (d, $J = 7.2$ Hz, 3H),

1.18 (d, $J = 7.2$ Hz, 3H). ^{13}C NMR (151 MHz, CD_3OD) δ 177.5, 169.7, 167.5 (d, $J = 258.2$ Hz, CF) 141.4, 136.7, 123.6, 122.1, 114.7, 114.5, 76.0, 52.4, 34.9, 28.8, 19.3, 19.2. ^{11}B NMR (192.5 MHz, CD_3OD) δ 28.3. HRMS (ESI⁺): m/z : Calcd. for $\text{C}_{16}\text{H}_{24}\text{BFNO}_5$ [$\text{M} + \text{H}$]⁺: 340.1726; Found: 340.1717.

(3-(2-(Tert-Butylamino)-1-(Isobutyryloxy)-2-Oxoethyl)-4-Methoxyphenyl)boronic Acid (**4d**)

Following general procedures, the desired compound was synthesized utilizing isobutyric acid (0.06 mL, 0.71 mmol), 3-formyl-4-methoxyphenylboronic acid (100 mg, 0.60 mmol), and tert-butyl isocyanide (0.08 mL, 0.71 mmol), giving compound **4d** as a yellow oil (yield 208.6 mg, 99%). ^1H NMR (600 MHz, CD_3OD) δ 7.82 (s, 1H), 7.77 (d, $J = 8.4$ Hz, 1H), 6.98 (t, $J = 8.4$ Hz, 1H), 6.21 (s, 1H), 3.87 (s, 3H), 2.17–2.66 (m, 1H), 1.33 (s, 9H), 1.20 (d, $J = 6.6$ Hz, 3H), 1.16 (d, $J = 6.6$ Hz, 3H). ^{13}C NMR (151 MHz, CD_3OD) δ 177.7, 170.5, 160.2, 137.4, 135.5, 124.4, 111.1, 71.9, 56.0, 52.3, 35.0, 28.8, 19.4, 19.2. ^{11}B NMR (192.5 MHz, CD_3OD) δ 28.3. HRMS (ESI⁺): m/z : Calcd. for $\text{C}_{17}\text{H}_{26}\text{BNO}_6$ [$\text{M} + \text{H}$]⁺: 352.1925; Found: 352.1918.

(5-(2-(Tert-Butylamino)-1-(Isobutyryloxy)-2-Oxoethyl)-2-Fluorophenyl)boronic Acid (**4e**)

Following general procedures, the desired compound was synthesized utilizing isobutyric acid (0.07 mL, 0.72 mmol), 2-fluoro-4-formylphenylboronic acid (100 mg, 0.60 mmol), and tert-butyl isocyanide (0.08 mL, 0.72 mmol), giving compound **4e** as a yellow oil (yield 134.3 mg, 66%). ^1H NMR (600 MHz, CD_3OD) δ 7.72 (br, 1H), 7.55–7.53 (m, 1H), 7.06 (t, $J = 9.0$ Hz, 1H), 5.83 (s, 1H), 2.72–2.67 (m, 1H), 1.29 (s, 9H), 1.20 (d, $J = 6.6$ Hz, 3H), 1.16 (d, $J = 6.6$ Hz, 3H). ^{13}C NMR (151 MHz, CD_3OD) δ 177.6, 167.7 (d, $J = 241.6$ Hz, CF), 135.8, 132.7, 132.3, 116.2, 116.1, 76.2, 52.4, 34.9, 28.8, 19.3, 19.2. ^{11}B NMR (192.5 MHz, CD_3OD) δ 28.6. HRMS (ESI⁺): m/z : Calcd. for $\text{C}_{16}\text{H}_{23}\text{BFNO}_5$ [$\text{M} + \text{Na}$]⁺: 362.1546; Found: 362.1546.

(4-(1-(Benzoyloxy)-2-(Tert-Butylamino)-2-Oxoethyl)phenyl)boronic Acid (**4f**)

Following general procedures, the desired compound was synthesized utilizing benzoic acid (0.12 mL, 0.80 mmol), 4-formyl phenylboronic acid (100 mg, 0.67 mmol), and tert-butyl isocyanide (0.10 mL, 0.80 mmol) giving compound **4f** as a yellow oil (yield 101.1 mg, 45%). ^1H NMR (600 MHz, CD_3OD) δ 8.08 (d, $J = 7.8$ Hz, 2H), 7.87 (s, 1H), 7.79 (s, 1H), 7.58 (q, $J = 22.2$ Hz, 3H), 7.46 (t, $J = 15.6$ Hz, 2H), 6.08 (s, 1H), 1.30 (s, 1H). ^{13}C NMR (151 MHz, CD_3OD) δ 170.4, 167.2, 135.3, 134.9, 134.7, 130.9, 129.7, 127.6, 77.5, 52.6, 28.9. ^{11}B NMR (192.5 MHz, CD_3OD) δ 28.6. HRMS (ESI⁺): m/z : Calcd. for $\text{C}_{19}\text{H}_{23}\text{BNO}_5$ [$\text{M} + \text{H}$]⁺: 356.1663; Found: 356.1656.

(4-(2-(Tert-Butylamino)-2-oxo-1-((Pyrazine-2-Carbonyl)oxy)ethyl)phenyl)boronic Acid (**4g**)

Following general procedures, the desired compound was synthesized utilizing pyrazine-2-carboxylic acid (99.30 mg, 0.80 mmol), 4-formyl phenylboronic acid (100 mg, 0.67 mmol), and tert-butyl isocyanide (0.10 mL, 0.80 mmol), giving compound **4g** as a yellow oil (yield 160.3 mg, 67%). ^1H NMR (300 MHz, CD_3OD) δ 9.32 (s, 1H), 8.84 (d, $J = 2.7$ Hz, 1H), 8.76 (s, 1H), 7.79–7.75 (m, 1H), 7.58 (s, 2H), 7.39 (d, $J = 13.8$ Hz, 1H), 6.16 (s, 1H), 1.33 (s, 9H). ^{13}C NMR (151 MHz, CD_3OD) δ 174.4, 169.8, 164.4, 149.6, 147.5, 146.1, 144.3, 135.1, 127.9, 127.2, 78.5, 75.7, 29.0. ^{11}B NMR (192.5 MHz, CD_3OD) δ 28.4. HRMS (ESI⁺): m/z : Calcd. for $\text{C}_{17}\text{H}_{20}\text{BN}_3\text{O}_5$ [$\text{M} + \text{Na}$]⁺: 380.1388; Found: 380.1385.

3.1.5. General Procedure for Compound **5a–l**

Carboxylic acid (1.2 equiv.), aldehyde (1.0 equiv.), and deionised H_2O (1.0 M) were reacted for 6 min under microwave irradiation (85 °C, 150 W). Isocyanide (1.2 equiv.) was then added to the reaction mixture. The additional microwave irradiation was applied for 2.5 h (85 °C, 150 W) under medium speed magnetic stirring. After the reaction was completed, the crude material was concentrated and re-dissolved in dichloromethane. The resulting organic solution was then washed with 1 M HCl (aq). This was followed by adding a saturated aqueous solution of NaHCO_3 (aq) combined with brine. The resulting organic layer

was collected, dried by MgSO_4 , and filtered. The filtrate was then concentrated in vacuo and the crude was precipitated by dichloromethane/ H_2O or dichloromethane/hexane sonication, and the resulting solid was collected by filtration to afford the desired product **5a–l**.

3.1.6. Synthesis and Characterization of Compound **5a–l**

(4-((2-(Tert-Butylamino)-2-Oxoethoxy)carbonyl)phenyl)boronic Acid (**5a**)

Following general procedures, the desired compound was synthesized utilizing 4-boronobenzoic acid (331.55 mg, 2.00 mmol), formaldehyde (0.16 mL, 1.67 mmol), and tert-butyl isocyanide (0.23 mL, 2.00 mmol), giving compound **5a** as a yellow oil (yield 344.9 mg, 74%). ^1H NMR (600 MHz, CD_3OD) δ 8.02 (d, $J = 7.2$ Hz, 2H), 7.86 (br, 2H), 4.69 (s, 2H), 1.36 (s, 9H). ^{13}C NMR (151 MHz, CD_3OD) δ 168.8, 167.5, 134.9, 129.7, 64.2, 52.2, 28.9. ^{11}B NMR (192.5 MHz, CD_3OD) δ 28.5. HRMS (ESI⁺): m/z : Calcd. for $\text{C}_{13}\text{H}_{19}\text{BNO}_5$ [$\text{M} + \text{H}$]⁺: 280.1350; Found: 280.1341.

(3-((2-(Tert-Butylamino)-2-Oxoethoxy)carbonyl)phenyl)boronic Acid (**5b**)

Following general procedures, the desired compound was synthesized utilizing 3-boronobenzoic acid (331.55 mg, 2.00 mmol), formaldehyde (0.16 mL, 1.67 mmol), and tert-butyl isocyanide (0.23 mL, 2.00 mmol), giving compound **5b** as a yellow oil (yield 256.4 mg, 55%). ^1H NMR (600 MHz, CD_3OD) δ 8.45 (br, 1H), 8.08 (d, $J = 7.8$ Hz, 1H), 8.00 (br, 1H), 7.48 (t, $J = 7.6$ Hz, 1H), 6.04 (br, 1H), 4.71 (s, 2H), 1.39 (s, 9H). ^{13}C NMR (151 MHz, CD_3OD) δ 166.6, 165.5, 138.9, 134.9, 131.6, 128.3, 128.1, 63.5, 51.6, 28.7. ^{11}B NMR (192.5 MHz, CD_3OD) δ 29.0. HRMS (ESI⁺): m/z : Calcd. for $\text{C}_{13}\text{H}_{19}\text{BNO}_5$ [$\text{M} + \text{H}$]⁺: 280.1350; Found: 280.1347.

(4-((2-(Tert-Butylamino)-2-Oxoethoxy)carbonyl)-3-Fluorophenyl)boronic Acid (**5c**)

Following general procedures, the desired compound was synthesized utilizing 4-borono-2-fluorobenzoic acid (367.49 mg, 2.00 mmol), formaldehyde (0.16 mL, 1.67 mmol), and tert-butyl isocyanide (0.23 mL, 2.00 mmol), giving compound **5c** as a yellow oil (yield 284.3 mg, 61%). ^1H NMR (600 MHz, CD_3OD) δ 7.90 (t, $J = 7.8$ Hz, 1H), 7.58 (br, 1H), 7.48 (br, 1H), 4.67 (s, 2H), 1.36 (s, 9H). ^{13}C NMR (151 MHz, CD_3OD) δ 168.5, 164.8, 162.7 (d, $J = 259.7$ Hz, CF), 132.3, 130.4, 122.7, 122.6, 119.9, 64.3, 52.4, 29.0. ^{11}B NMR (192.5 MHz, CD_3OD) δ 27.7. HRMS (ESI⁺): m/z : Calcd. for $\text{C}_{13}\text{H}_{17}\text{BFNO}_5$ [$\text{M} + \text{H}$]⁺: 298.1256; Found: 298.1245.

(4-((2-(Tert-Butylamino)-2-Oxo-1-Phenylethoxy)carbonyl)phenyl)boronic Acid (**5d**)

Following general procedures, the desired compound was synthesized utilizing 4-boronobenzoic acid (93.83 mg, 0.57 mmol), benzaldehyde (0.05 mL, 0.47 mmol), and tert-butyl isocyanide (0.06 mL, 0.57 mmol), giving compound **5d** as a yellow oil (yield 75.1 mg, 45%). ^1H NMR (600 MHz, CD_3OD) δ 8.04 (d, $J = 7.8$ Hz, 2H), 7.85 (br, 1H), 7.59 (d, $J = 7.8$ Hz, 2H), 7.37 (m, 3H), 6.07 (s, 1H), 1.30 (s, 9H). ^{13}C NMR (151 MHz, CD_3OD) δ 170.4, 167.3, 140.7, 137.3, 134.9, 131.4, 130.9, 130.0, 77.5, 52.5, 28.9. ^{11}B NMR (192.5 MHz, CD_3OD) δ 27.9. HRMS (ESI⁺): m/z : Calcd. for $\text{C}_{19}\text{H}_{22}\text{BNO}_5$ [$\text{M} + \text{H}$]⁺: 356.1663; Found: 356.1656.

(4-((2-(Cyclohexylamino)-2-Oxo-1-Phenylethoxy)carbonyl)phenyl)boronic Acid (**5e**)

Following general procedures, the desired compound was synthesized utilizing 4-boronobenzoic acid (93.83 mg, 0.57 mmol), benzaldehyde (0.05 mL, 0.47 mmol), and cyclohexyl isocyanide (0.07 mL, 0.57 mmol), giving compound **5e** as a yellow oil (yield 161.3 mg, 90%). ^1H NMR (600 MHz, CD_3OD) δ 8.05 (d, $J = 8.4$ Hz, 2H), 7.82 (br, 1H), 7.58 (d, $J = 7.2$ Hz, 2H), 7.43–7.37 (m, 3H), 6.10 (s, 1H), 3.67–3.63 (m, 1H), 1.91–1.60 (m, 5H), 1.36–1.20 (m, 5H). ^{13}C NMR (151 MHz, CD_3OD) δ 170.3, 167.3, 137.0, 134.8, 129.9, 129.7, 129.6, 128.4, 77.4, 33.5, 33.3, 26.5, 26.0, 26.0. ^{11}B NMR (192.5 MHz, CD_3OD) δ 27.0. HRMS (ESI⁺): m/z : Calcd. for $\text{C}_{21}\text{H}_{24}\text{BNO}_5$ [$\text{M} + \text{H}$]⁺: 382.1820; Found: 382.1823.

(4-((1-(4-Bromophenyl)-2-(Tert-Butylamino)-2-Oxoethoxy)carbonyl)phenyl)boronic Acid (5f)

Following general procedures, the desired compound was synthesized utilizing 4-boronobenzoic acid (107.60 mg, 0.65 mmol), 4-bromobenzaldehyde (100 mg, 0.54 mmol), and tert-butyl isocyanide (0.07 mL, 0.65 mmol), giving compound 5f as a yellow oil (yield 157.1 mg, 67%). ¹H NMR (600 MHz, CD₃OD) δ 8.13 (s, 2H), 8.03–7.84 (m, 2H), 7.71 (s, 2H), 7.61 (q, *J* = 12 Hz, 2H), 6.05 (s, 1H), 1.30 (s, 9H). ¹³C NMR (151 MHz, CDCl₃) δ 167.4, 164.9, 134.6, 134.0, 133.6, 132.0, 130.7, 129.0, 128.8, 123.2, 51.9, 28.6. ¹¹B NMR (192.5 MHz, CD₃OD) δ 27.9. HRMS (ESI⁺): *m/z*: Calcd. for C₁₉H₂₁BBrNO₅ [M + H]⁺: 434.0760; Found: 434.0768.

(4-((2-(Tert-Butylamino)-1-(4-Fluorophenyl)-2-oxoethoxy)carbonyl)phenyl)boronic Acid (5g)

Following general procedures, the desired compound was synthesized utilizing 4-boronobenzoic acid (80.20 mg, 0.48 mmol), 4-fluorobenzaldehyde (50.00 mg, 0.40 mmol), and tert-butyl isocyanide (0.05 mL, 0.48 mmol), giving compound 5g as a yellow oil (yield 128.4 mg, 86%). ¹H NMR (600 MHz, CD₃OD) δ 8.04 (d, *J* = 5.4 Hz, 2H), 7.90 (s, 1H), 7.85 (br, 1H), 7.64–7.61 (m, 2H), 7.14 (t, *J* = 9.0 Hz, 2H), 6.07 (s, 1H), 1.31 (s, 9H). ¹³C NMR (151 MHz, CD₃OD) δ 170.4, 167.3, 164.5 (d, *J* = 247.6 Hz, CF), 135.1, 134.7, 133.5, 130.8, 130.7, 129.8, 116.6, 116.5, 76.8, 52.7, 28.9. ¹¹B NMR (192.5 MHz, CD₃OD) δ 28.1. HRMS (ESI⁺): *m/z*: Calcd. for C₁₉H₂₁BFNO₅ [M + H]⁺: 374.1561; Found: 374.1569.

(4-((2-(Tert-Butylamino)-1-(2-Fluorophenyl)-2-oxoethoxy)carbonyl)phenyl)boronic Acid (5h)

Following general procedures, the desired compound was synthesized utilizing 4-boronobenzoic acid (80.20 mg, 0.48 mmol), 2-fluorobenzaldehyde (50.00 mg, 0.40 mmol), and tert-butyl isocyanide (0.05 mL, 0.48 mmol), giving compound 5h as a yellow oil (yield 67.2 mg, 45%). ¹H NMR (600 MHz, CD₃OD) δ 8.00 (d, *J* = 7.8 Hz, 2H), 7.83 (s, 1H), 7.72 (s, 1H), 7.61 (t, *J* = 7.2 Hz, 1H), 7.39–7.34 (m, 1H), 7.22–7.17 (m, 1H), 7.14–7.10 (m, 1H), 6.41 (s, 1H), 1.29 (s, 1H). ¹³C NMR (151 MHz, CD₃OD) δ 169.2, 167.0, 162.1 (d, *J* = 249.2 Hz, CF), 134.9, 132.2, 125.6, 124.6, 116.6, 71.4, 52.7, 28.9. ¹¹B NMR (192.5 MHz, CD₃OD) δ 28.3. HRMS (ESI⁺): *m/z*: Calcd. for C₁₉H₂₁BFNO₅ [M + Na]⁺: 396.1389; Found: 396.1392.

(4-((2-(Tert-Butylamino)-2-Oxo-1-(Quinolin-4-yl)ethoxy)carbonyl)phenyl)boronic Acid (5i)

Following general procedures, the desired compound was synthesized utilizing 4-boronobenzoic acid (63.34 mg, 0.38 mmol), quinoline-4-carbaldehyde (50.00 mg, 0.32 mmol), and tert-butyl isocyanide (0.43 mL, 0.38 mmol), giving compound 5i as a yellow oil (yield 59.8 mg, 46%). ¹H NMR (600 MHz, CD₃OD) δ 8.89 (s, 1H), 8.37 (d, *J* = 8.4 Hz, 1H), 8.08 (d, *J* = 8.4 Hz, 1H), 8.01 (d, *J* = 7.8 Hz, 2H), 8.79 (t, *J* = 7.8 Hz, 3H), 7.75 (d, *J* = 4.2 Hz, 1H), 7.67 (t, *J* = 7.8 Hz, 1H), 6.86 (s, 1H), 1.32 (s, 9H). ¹³C NMR (151 MHz, CD₃OD) δ 168.7, 167.0, 151.1, 149.3, 143.9, 134.9, 131.2, 130.2, 129.8, 128.7, 127.6, 125.5, 121.9, 74.3, 52.9, 28.8. ¹¹B NMR (192.5 MHz, CD₃OD) δ 26.9. HRMS (ESI⁺): *m/z*: Calcd. for C₂₂H₂₃BN₂O₅ [M + H]⁺: 407.1759; Found: 407.1772.

(4-((2-(Cyclohexylamino)-2-oxo-1-(Quinolin-4-yl)ethoxy)carbonyl)phenyl)boronic Acid (5j)

Following general procedures, the desired compound was synthesized utilizing 4-boronobenzoic acid (63.34 mg, 0.38 mmol), quinoline-4-carbaldehyde (50.00 mg, 0.32 mmol), and cyclohexyl isocyanide (0.48 mL, 0.38 mmol), giving compound 5j as a yellow oil (yield 112.0 mg, 81%). ¹H NMR (600 MHz, CD₃OD) δ 8.90 (d, *J* = 4.8 Hz, 1H), 8.41 (d, *J* = 8.4 Hz, 1H), 8.10 (d, *J* = 8.4 Hz, 1H), 8.04 (d, *J* = 8.4 Hz, 2H), 7.83–7.77 (m, 4H), 7.69 (t, *J* = 7.8 Hz, 1H), 6.90 (s, 1H), 3.70–3.67 (m, 1H), 1.89–1.57 (m, 5H), 1.35–1.19 (m, 5H). ¹³C NMR (151 MHz, CD₃OD) δ 167.9, 166.2, 150.4, 148.5, 142.9, 134.3, 130.5, 129.4, 129.1, 128.0, 126.7, 124.8, 121.2, 73.5, 32.7, 32.6, 25.8, 25.4. ¹¹B NMR (192.5 MHz, CD₃OD) δ 27.2. HRMS (ESI⁺): *m/z*: Calcd. for C₂₄H₂₅BN₂O₅ [M + H]⁺: 433.1929; Found: 433.1908.

(4-((2-(Cyclohexylamino)-1-(4-Fluorophenyl)-2-Oxoethoxy)carbonyl)phenyl)boronic Acid (**5k**)

Following general procedures, the desired compound was synthesized utilizing 4-boronobenzoic acid (63.34 mg, 0.38 mmol), 4-fluorobenzaldehyde (0.03 mL, 0.32 mmol), and cyclohexyl isocyanide (0.48 mL, 0.38 mmol), giving compound **5k** as a yellow oil (yield 104.7 mg, 82%). ^1H NMR (600 MHz, CD_3OD) δ 8.05 (s, 2H), 7.85 (br, 1H), 7.72 (br, 1H), 7.63–7.61 (m, 2H), 7.14 (t, $J = 9.0$ Hz, 2H), 6.08 (s, 1H), 3.66–3.62 (m, 1H), 1.91–1.60 (m, 5H), 1.35–1.17 (m, 5H). ^{13}C NMR (151 MHz, CD_3OD) δ 170.2, 167.2, 164.6 (d, $J = 246.1$ Hz, CF), 135.1, 134.6, 133.3, 130.8, 130.7, 129.9, 116.7, 116.5, 76.8, 33.6, 33.5, 26.7, 26.2. ^{11}B NMR (192.5 MHz, CD_3OD) δ 11.5. HRMS (ESI⁺): m/z : Calcd. for $\text{C}_{21}\text{H}_{23}\text{BFNO}_5$ $[\text{M} - \text{H}]^-$: 398.1581; Found: 398.1576.

(4-((2-(Tert-Butylamino)-2-Oxoethoxy)carbonyl)-2-Nitrophenyl)boronic Acid (**5l**)

Following general procedures, the desired compound was synthesized utilizing 4-borono-3-nitrobenzoic acid (421.9 mg, 2.00 mmol), formaldehyde (0.16 mL, 1.67 mmol), and tert-butyl isocyanide (0.23 mL, 2.00 mmol), giving compound **5l** as a yellow oil (yield 346.4 mg, 64%). ^1H NMR (600 MHz, CD_3OD) δ 8.85 (s, 1H), 8.50–8.44 (m, 1H), 7.78 (t, $J = 7.8$ Hz, 1H), 4.78 (s, 2H), 1.38 (s, 9H). ^{13}C NMR (151 MHz, CD_3OD) δ 168.5, 165.4, 149.7, 136.5, 132.7, 131.2, 128.7, 125.4, 64.6, 52.4, 28.9. HRMS (ESI⁺): m/z : Calcd. for $\text{C}_{13}\text{H}_{17}\text{BN}_2\text{O}_5$ $[\text{M} + \text{H}]^+$: 325.1202; Found: 325.1122.

3.2. Cell Line and Cell Culture

HEK293 cells and human embryonic kidney cells were obtained from the American Type Culture Collection. The cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% FBS, 100 U/mL penicillin and 100 mg/mL streptomycin at 37 °C under 5% CO_2 .

3.3. Toxicity Analysis

HEK293 cells were plated at 70% density in 24-well plates at 37 °C. All compounds were first dissolved in 100% DMSO to give 1 mM as a stock for the following dilutions. The cells were treated with all compounds except **4e**, **5a**, **5h**, **5i**, **5l** (for their poor solubility issues) at the dose of 1, 10 and 50 μM for 48h. Further, the cell viability was measured by the 3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay. After incubating for 1h, the reaction product was read at 570 nm using a Synergy HT microplate reader (BioTek Instruments, Winooski, VT, USA).

3.4. Cellular Bio-Distribution

HEK293 cells were treated with compound **4a**, **5b**, **5f**, **5g** and **5k** (1 mM or 2 mM) for 2h. Then, cells were added DAHMI (2 mM) for another 1h. The complex of DAHMI-Boronic acid compound has an excitation/emission at ~358/461 nm. The distributions of boronic acid compounds were observed by fluorescence microscopy using an Olympus CX Microscope.

4. Conclusions

In conclusion, we have developed a boronic acid protection-free microwave-assisted condition to construct two series of depsipeptide boronic acids. The mechanistic study using ^{11}B NMR spectrum and theoretical calculations suggested that the location of the boronic acid group plays a significant role in influencing the overall yields. This reported strategy enables the facile relocation of the boronic acid within the molecular framework. Furthermore, the synthesized boronic acids could be subjected to linker-free tagging experiments, where their bio-distribution profiles can be directly assessed.

Supplementary Materials: The following supporting information can be downloaded <https://www.mdpi.com/article/10.3390/molecules27072325/s1>. Figure S1. The ^1H NMR spectrum of **4a** in

CD3OD; Figure S2. The ^{13}C NMR spectrum of 4a in CD3OD; Figure S3. The ^{11}B NMR spectrum of 4a in CD3OD; Figure S4. The HRMS (ESI+) of spectrum of 4a; Figure S5. The ^1H NMR spectrum of 4b in CD3OD; Figure S6. The ^{13}C NMR spectrum of 4b in CD3OD; Figure S7. The ^{11}B NMR spectrum of 4b in CD3OD; Figure S8. The HRMS (ESI+) of spectrum of 4b; Figure S9. The ^1H NMR spectrum of 4c in CD3OD; Figure S10. The ^{13}C NMR spectrum of 4c in CD3OD; Figure S11. The ^{11}B NMR spectrum of 4c in CD3OD; Figure S12. The HRMS (ESI+) of spectrum of 4c; Figure S13. The ^1H NMR spectrum of 4d in CD3OD; Figure S14. The ^{13}C NMR spectrum of 4d in CD3OD; Figure S15. The ^{11}B NMR spectrum of 4d in CD3OD; Figure S16. The HRMS (ESI+) of spectrum of 4d; Figure S17. The ^1H NMR spectrum of 4e in CD3OD; Figure S18. The ^{13}C NMR spectrum of 4e in CD3OD; Figure S19. The ^{11}B NMR spectrum of 4e in CD3OD; Figure S20. The HRMS (ESI+) of spectrum of 4e; Figure S21. The ^1H NMR spectrum of 4f in CD3OD; Figure S22. The ^{13}C NMR spectrum of 4f in CD3OD; Figure S23. The ^{11}B NMR spectrum of 4f in CD3OD; Figure S24. The HRMS (ESI+) of spectrum of 4f; Figure S25. The ^1H NMR spectrum of 4g in CD3OD; Figure S26. The ^{13}C NMR spectrum of 4g in CD3OD; Figure S27. The ^{11}B NMR spectrum of 4g in CD3OD; Figure S28. The HRMS (ESI+) of spectrum of 4g; Figure S29. The ^1H NMR spectrum of 5a in CD3OD; Figure S30. The ^{13}C NMR spectrum of 5a in CD3OD; Figure S31. The ^{11}B NMR spectrum of 5a in CD3OD; Figure S32. The HRMS (ESI+) of spectrum of 5a; Figure S33. The ^1H NMR spectrum of 5b in CD3OD; Figure S34. The ^{13}C NMR spectrum of 5b in CD3OD; Figure S35. The ^{11}B NMR spectrum of 5b in CD3OD; Figure S36. The HRMS (ESI+) of spectrum of 5b; Figure S37. The ^1H NMR spectrum of 5c in CD3OD; Figure S38. The ^{13}C NMR spectrum of 5c in CD3OD; Figure S39. The ^{11}B NMR spectrum of 5c in CD3OD; Figure S40. The HRMS (ESI+) of spectrum of 5c; Figure S41. The ^1H NMR spectrum of 5d in CD3OD; Figure S42. The ^{13}C NMR spectrum of 5d in CD3OD; Figure S43. The ^{11}B NMR spectrum of 5d in CD3OD; Figure S44. The HRMS (ESI+) of spectrum of 5d; Figure S45. The ^1H NMR spectrum of 5e in CD3OD; Figure S46. The ^{13}C NMR spectrum of 5e in CD3OD; Figure S47. The ^{11}B NMR spectrum of 5e in CD3OD; Figure S48. The HRMS (ESI+) of spectrum of 5e; Figure S49. The ^1H NMR spectrum of 5f in CD3OD; Figure S50. The ^{13}C NMR spectrum of 5f in CDCl₃; Figure S51. The ^{11}B NMR spectrum of 5f in CD3OD; Figure S52. The HRMS (ESI+) of spectrum of 5f; Figure S53. The ^1H NMR spectrum of 5g in CD3OD; Figure S54. The ^{13}C NMR spectrum of 5g in CD3OD; Figure S55. The ^{11}B NMR spectrum of 5g in CD3OD; Figure S56. The HRMS (ESI+) of spectrum of 5g; Figure S57. The ^1H NMR spectrum of 5h in CD3OD; Figure S58. The ^{13}C NMR spectrum of 5h in CD3OD; Figure S59. The ^{11}B NMR spectrum of 5h in CD3OD; Figure S60. The HRMS (ESI+) of spectrum of 5h; Figure S61. The ^1H NMR spectrum of 5i in CD3OD; Figure S62. The ^{13}C NMR spectrum of 5i in CD3OD; Figure S63. The ^{11}B NMR spectrum of 5i in CD3OD; Figure S64. The HRMS (ESI+) of spectrum of 5i; Figure S65. The ^1H NMR spectrum of 5j in CD3OD; Figure S66. The ^{13}C NMR spectrum of 5j in CD3OD; Figure S67. The ^{11}B NMR spectrum of 5j in CD3OD; Figure S68. The HRMS (ESI+) of spectrum of 5j; Figure S69. The ^1H NMR spectrum of 5k in CD3OD; Figure S70. The ^{13}C NMR spectrum of 5k in CD3OD; Figure S71. The ^{11}B NMR spectrum of 5k in CD3OD; Figure S72. The HRMS (ESI-) of spectrum of 5k; Figure S73. The ^1H NMR spectrum of 5l in CD3OD; Figure S74. The ^{13}C NMR spectrum of 5l in CD3OD; Figure S75. The HRMS (ESI+) of spectrum of 5l; Figure S76. The cytotoxicity of the compounds 4a–4d, 4f and 4g in HEK-293 cells; Figure S77. The cytotoxicity of the compounds 5b–5g, 5j and 5k in HEK-293 cells.

Author Contributions: Conceptualization, Y.-W.C. and Y.-C.C.; methodology, S.-B.Q.; software, B.-C.W.; validation, P.-S.P., Y.-C.C. and J.-K.C.; formal analysis, S.-B.Q. and P.-Y.L.; investigation, S.-B.Q., P.-R.C., J.-H.X., T.-Y.H., K.-L.P. and Z.-Y.L.; data curation, S.-B.Q.; writing—P.-S.P., Y.-C.C. and J.-K.C.; All authors have read and agreed to the published version of the manuscript.

Funding: This research was supported by the Ministry of Science and Technology in Taiwan (MOST-108-2113-M-032-005, MOST-108-2623-E-032-001-NU).

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Acknowledgments: We thank Department of Chemistry of Tamkang University for the equipment and financial support. We thank Shen-Shen Chen for conducting ^{11}B NMR experiments. We thank Ping-Yu Lin, Institute of Chemistry, Academia Sinica for conducting HRMS experiments. We thank Jiann-Long Yan, National Health Research Institutes for conducting HRMS experiments.

Conflicts of Interest: The authors declare that they have no conflict of interest.

Sample Availability: Samples of the compounds 4a–g and 5a–l are available from the authors.

References

1. Bull, S.; Davidson, M.; van den Elsen, J.; Fossey, J.; Jenkins, A.; Jiang, Y.; Kubo, Y.; Marken, F.; Sakurai, K.; Zhao, J.; et al. Exploiting the Reversible Covalent Bonding of Boronic Acids: Recognition, Sensing, and Assembly. *Acc. Chem. Res.* **2012**, *46*, 312–326. [[CrossRef](#)] [[PubMed](#)]
2. Molander, G.A.; Trice, S.L.; Tschaen, B. A modified procedure for the palladium catalyzed borylation/Suzuki-Miyaura cross-coupling of aryl and heteroaryl halides utilizing bis-boronic acid. *Tetrahedron* **2015**, *71*, 5758–5764. [[CrossRef](#)] [[PubMed](#)]
3. Wang, S.; Wang, Y.; Bian, C.; Zhong, Y.; Jing, X. The thermal stability and pyrolysis mechanism of boron-containing phenolic resins: The effect of phenyl borates on the char formation. *Appl. Surf. Sci.* **2015**, *331*, 519–529. [[CrossRef](#)]
4. Messersmith, R.E.; Siegler, M.A.; Tovar, J.D. Aromaticity Competition in Differentially Fused Borepin-Containing Polycyclic Aromatics. *J. Org. Chem.* **2016**, *81*, 5595–5605. [[CrossRef](#)] [[PubMed](#)]
5. Baker, S.J.; Ding, C.Z.; Akama, T.; Zhang, Y.-K.; Hernandez, V.; Xia, Y. Therapeutic potential of boron-containing compounds. *Future. Med. Chem.* **2009**, *1*, 1275–1288. [[CrossRef](#)] [[PubMed](#)]
6. Smoum, R.; Rubinstein, A.; Dembitsky, V.M.; Srebnik, M. Boron Containing Compounds as Protease Inhibitors. *Chem. Rev.* **2012**, *112*, 4156–4220. [[CrossRef](#)] [[PubMed](#)]
7. Correy, G.J.; Zaidman, D.; Harmelin, A.; Carvalho, S.; Mabbitt, P.D.; Calaora, V.; James, P.J.; Kotze, A.C.; Jackson, C.J.; London, N. Overcoming insecticide resistance through computational inhibitor design. *Proc. Natl. Acad. Sci. USA* **2019**, *116*, 21012–21021. [[CrossRef](#)] [[PubMed](#)]
8. Hua, Y.; Nair, S. Proteases in cardiometabolic diseases: Pathophysiology, molecular mechanisms and clinical applications. *Biochim. Biophys. Acta Mol. Basis Dis.* **2015**, *1852*, 195–208. [[CrossRef](#)] [[PubMed](#)]
9. Molander, G.A.; Ellis, N. Organotrifluoroborates: Protected Boronic Acids That Expand the Versatility of the Suzuki Coupling Reaction. *Acc. Chem. Res.* **2007**, *40*, 275–286. [[CrossRef](#)]
10. Lian, R.-C.; Lin, M.-H.; Liao, P.-H.; Fu, J.-J.; Wu, M.-J.; Wu, Y.-C.; Chang, F.-R.; Wu, C.-C.; Pan, P.-S. Direct synthesis of the arylboronic acid analogues of phenylglycine via microwave-assisted four-component Ugi reaction. *Tetrahedron* **2014**, *70*, 1800–1804. [[CrossRef](#)]
11. Ramírez-Ornelas, D.E.; Sola-Llano, R.; Bañuelos, J.; Arbeloa, I.L.; Martínez-Álvarez, J.A.; Mora-Montes, H.M.; Franco, B.; PeñaCabrera, E. Synthesis, Photophysical Study, and Biological Application Analysis of Complex Borondipyromethene Dyes. *ACS Omega* **2018**, *3*, 7783–7797. [[CrossRef](#)]
12. Neochoritis, C.G.; Zarganes-Tzitzikas, T.; Novotná, M.; Mitriková, T.; Wang, Z.; Kurpiewska, K.; Kalinowska-Thučik, J.; Dömling, A. Isocyanide-Based Multicomponent Reactions of Free Phenylboronic Acids. *Eur. J. Org. Chem.* **2019**, *35*, 6132–6137. [[CrossRef](#)]
13. Chai, C.-C.; Liu, P.-Y.; Lin, C.-H.; Chen, H.-C.; Wu, Y.-C.; Chang, F.-R.; Pan, P.-S. Efficient Synthesis of Boron-Containing α -Acylxyamide Analogs via Microwave Irradiation. *Molecules* **2013**, *18*, 9488–9511. [[CrossRef](#)] [[PubMed](#)]
14. Barth, R.F.; Coderre, J.A.; Vicente, M.G.H.; Blue, T.E. Boron neutron capture therapy of cancer: Current status and future prospects. *Clin. Cancer Res.* **2005**, *11*, 3987–4002. [[CrossRef](#)] [[PubMed](#)]
15. Barth, R.F.; Mi, P.; Yang, W. Boron delivery agents for neutron capture therapy of cancer. *Cancer Commun.* **2018**, *38*, 35. [[CrossRef](#)] [[PubMed](#)]
16. Hattori, Y.; Ishimura, M.; Ohta, Y.; Takenaka, H.; Watanabe, T.; Tanaka, H.; Ono, K.; Kirihata, M. Detection of boronic acid derivatives in cells using a fluorescent sensor. *Org. Biomol. Chem.* **2015**, *13*, 6927–6930. [[CrossRef](#)] [[PubMed](#)]
17. Tanaka, H.; Sakurai, Y.; Suzuki, M.; Masunaga, S.-I.; Takamiya, K.; Maruhashi, A.; Ono, K. Development of a simple and rapid method of precisely identifying the position of ^{10}B atoms in tissue: An improvement in standard alpha autoradiography. *J. Radiat. Res.* **2013**, *55*, 373–380. [[CrossRef](#)] [[PubMed](#)]
18. Hattori, Y.; Kusaka, S.; Mukumoto, M.; Uehara, K.; Asano, T.; Suzuki, M.; Masunaga, S.-I.; Ono, K.; Tanimori, S.; Kirihata, M. Biological Evaluation of Dodecaborate-Containing l-Amino Acids for Boron Neutron Capture Therapy. *J. Med. Chem.* **2012**, *55*, 6980–6984. [[CrossRef](#)] [[PubMed](#)]